A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease.

Inclusion Criteria: * 1\. Signed Informed Consent； * 2\. According to the Diagnostic Criterion for Crohn's Disease in China's 《Consensus on the Diagnosis and Treatment of Inflammatory Bowel Disease》 (2018, Beijing), Crohn's disease was diagnosed at least 6 months before the screening period； * 3\. Crohn's disease activity index (CDAI) score of 220 or less is defined as inactive or mildly active luminal Crohn's disease； * 4\. Through clinical evaluation, MRI evaluation for anal fistula patients； * 5\. Age 18 \~ 70, male or female； * 6\. The serum or urine pregnancy test of a woman of reproductive age must be negative. Both men and women must agree to use a contraceptive method； * 7\. According to the history and related examination, the general health condition is good； * 8\. The eligible patients must at least meet one of the following conditions: patients who have failed to respond to any conventional treatment, such as conventional antibiotic therapy, immunomodulatory drug therapy, anti-tumor necrosis factor (TNF) α monoclonal antibody therapy, and 5-aminosalicylic acid Exclusion Criteria: * 1\. CDAI \> 220, or due to Crohn's disease activity, treatment needs to be upgraded immediately； * 2\. Patients with abdominal and pelvic abscess or fistula diameter more than 2 cm； * 3\. Patients with rectal and/or anal stenosis and/or active proctitis (due to limited surgical procedures)； * 4\. The number of internal and / or external openings of anal fistula was more than 2 and 3 respectively; * 5\. Patients who received steroid therapy within the first 4 weeks were screened； * 6\. Abnormal laboratory test results： Liver function: total bilirubin ≥1.5 times the upper limit of normal value, aspartate aminotransferase (AST) or alanine aminotransferase (ALT)≥2.5 times the upper limit of normal value; Renal function: Creatinine clearance below 60mL/min or 1.5 times the upper normal limit of serum creatinine (measured value or calculated by the Cockcroft-Gault formula)； * 7.Patients with malignancy or a history of malignancy, including fistula cancer of any type； * 8\. Patients with severe, progressive, uncontrollable diseases of the liver, blood, gastrointestinal (except Crohn's disease), endocrine, lung, heart, neurological, psychiatric, or brain； * 9\. HIV, syphilis antibody positive, HCV / HBV positive, tuberculosis in the infectious period, etc; * 10\. Patients who are allergic to human serum albumin, human platelet lysates, anesthetic agents or contrast agents； * 11\. Patients with contraindications to MRI scanning； * 12\. Pregnant or lactating women and subjects who cannot commit to using effective contraceptives during the trial and for 6 months after the end of the trial； * 13\. Patients who have undergone major surgery or severe trauma in the past six months； * 14\. Patients who had received any study drug within a certain period of time prior to screening； * 15.Patients deemed ineligible to participate in this clinical trial by the investigator